Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

A new therapeutic approach in very refractory diffuse large B-cell lymphoma.

Avilés A, Nambo MJ, Neri N, Cleto S, Silva L.

Clin Transl Oncol. 2019 Jul 29. doi: 10.1007/s12094-019-02172-1. [Epub ahead of print]

PMID:
31359338
2.

Retracted article: Adjuvant radiotherapy in patients with diffuse large B-cell lymphoma in advanced stage (III/IV) improves the outcome in the rituximab era.

Avilès A, Nambo MJ, Calva A, Neri N, Cleto S, Silva L.

Hematology. 2019 Dec;24(1):521-525. doi: 10.1080/10245332.2018.1423880. Epub 2018 Jan 17. Retraction in: Hematology. 2019 Dec;24(1):526.

PMID:
29338665
3.

An Engineered Synthetic Pathway for Discovering Nonnatural Nonribosomal Peptides in Escherichia coli.

Cleto S, Lu TK.

MBio. 2017 Oct 10;8(5). pii: e01474-17. doi: 10.1128/mBio.01474-17.

4.

Prolonged Use of Zoledronic Acid (4 Years) Did Not Improve Outcome in Multiple Myeloma Patients.

Avilès A, Nambo MJ, Huerta-Guzmàn J, Cleto S, Neri N.

Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):207-210. doi: 10.1016/j.clml.2017.02.007. Epub 2017 Feb 16.

PMID:
28284745
5.

Hemodiafiltration Decreases Serum Levels of Inflammatory Mediators in Severe Leptospirosis: A Prospective Study.

Cleto SA, Rodrigues CE, Malaque CM, Sztajnbok J, Seguro AC, Andrade L.

PLoS One. 2016 Aug 3;11(8):e0160010. doi: 10.1371/journal.pone.0160010. eCollection 2016.

6.

Synthetic biology and microbioreactor platforms for programmable production of biologics at the point-of-care.

Perez-Pinera P, Han N, Cleto S, Cao J, Purcell O, Shah KA, Lee K, Ram R, Lu TK.

Nat Commun. 2016 Jul 29;7:12211. doi: 10.1038/ncomms12211.

7.

Genetically Engineered Phages: a Review of Advances over the Last Decade.

Pires DP, Cleto S, Sillankorva S, Azeredo J, Lu TK.

Microbiol Mol Biol Rev. 2016 Jun 1;80(3):523-43. doi: 10.1128/MMBR.00069-15. Print 2016 Sep. Review.

8.

Corynebacterium glutamicum Metabolic Engineering with CRISPR Interference (CRISPRi).

Cleto S, Jensen JV, Wendisch VF, Lu TK.

ACS Synth Biol. 2016 May 20;5(5):375-85. doi: 10.1021/acssynbio.5b00216. Epub 2016 Feb 16.

9.

Engineering Synthetic Gene Circuits in Living Cells with CRISPR Technology.

Jusiak B, Cleto S, Perez-Piñera P, Lu TK.

Trends Biotechnol. 2016 Jul;34(7):535-547. doi: 10.1016/j.tibtech.2015.12.014. Epub 2016 Jan 22. Review.

PMID:
26809780
10.

Speckle-Tracking Echocardiography to Detect Cardiac Toxicity in Children Who Received Anthracyclines During Pregnancy.

Avilès A, Nambo MJ, Huerta-Guzmàn J, Neri N, Cleto S.

Clin Lymphoma Myeloma Leuk. 2016 Jan;16(1):1-4. doi: 10.1016/j.clml.2015.09.009. Epub 2015 Oct 9.

PMID:
26549215
11.

Chemopreventive effects of rosmarinic acid on rat colon carcinogenesis.

Furtado RA, Oliveira BR, Silva LR, Cleto SS, Munari CC, Cunha WR, Tavares DC.

Eur J Cancer Prev. 2015 Mar;24(2):106-12. doi: 10.1097/CEJ.0000000000000055.

PMID:
24977626
12.

Genome Sequence of Serratia plymuthica V4.

Cleto S, Van der Auwera G, Almeida C, Vieira MJ, Vlamakis H, Kolter R.

Genome Announc. 2014 May 15;2(3). pii: e00340-14. doi: 10.1128/genomeA.00340-14.

13.

Mixing and matching siderophore clusters: structure and biosynthesis of serratiochelins from Serratia sp. V4.

Seyedsayamdost MR, Cleto S, Carr G, Vlamakis H, João Vieira M, Kolter R, Clardy J.

J Am Chem Soc. 2012 Aug 22;134(33):13550-3. doi: 10.1021/ja304941d. Epub 2012 Aug 13.

14.

Characterization of contaminants from a sanitized milk processing plant.

Cleto S, Matos S, Kluskens L, Vieira MJ.

PLoS One. 2012;7(6):e40189. doi: 10.1371/journal.pone.0040189. Epub 2012 Jun 28.

15.

Prevalence of primary drug resistance-associated mutations among HIV type 1 vertically Infected children in Belo Horizonte, Brazil.

Ferreira FG, Pinto JA, Kakehasi FM, Cleto S, Tupinambás U, Aleixo AW, Cardoso CS.

AIDS Res Hum Retroviruses. 2010 Feb;26(2):229-32. doi: 10.1089/aid.2009.0146.

PMID:
20156105
16.

Early identification of leptospirosis-associated pulmonary hemorrhage syndrome by use of a validated prediction model.

Marotto PC, Ko AI, Murta-Nascimento C, Seguro AC, Prado RR, Barbosa MC, Cleto SA, Eluf-Neto J.

J Infect. 2010 Mar;60(3):218-23. doi: 10.1016/j.jinf.2009.12.005. Epub 2009 Dec 21.

17.

Rituximab and dose-dense chemotherapy in primary testicular lymphoma.

Avilés A, Nambo MJ, Cleto S, Neri N, Huerta-Guzmán J.

Clin Lymphoma Myeloma. 2009 Oct;9(5):386-9. doi: 10.3816/CLM.2009.n.075.

PMID:
19858059
18.

Rituximab and chemotherapy in primary gastric lymphoma.

Avilés A, Castañeda C, Cleto S, Neri N, Huerta-Guzmán J, Gonzalez M, Nambo MJ.

Cancer Biother Radiopharm. 2009 Feb;24(1):25-8. doi: 10.1089/cbr.2008.0507.

PMID:
19216628
19.

Results of a phase III clinical trial: CHOP versus CMED in peripheral T-cell lymphoma unspecified.

Avilés A, Castañeda C, Neri N, Cleto S, Talavera A, González M, Huerta-Guzmán J, Nambo MJ.

Med Oncol. 2008;25(3):360-4. doi: 10.1007/s12032-008-9046-2. Epub 2008 Feb 5.

PMID:
18247163
20.

Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy.

Kakehasi FM, Tupinambás U, Cleto S, Aleixo A, Lin E, Melo VH, Aguiar RA, Pinto JA.

AIDS Res Hum Retroviruses. 2007 Dec;23(12):1515-20.

PMID:
18160009
21.

Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Sézary syndrome.

Avilés A, Nambo MJ, Neri N, Castañeda C, Cleto S, Gonzalez M, Huerta-Guzmán J.

Cancer Biother Radiopharm. 2007 Dec;22(6):836-40.

PMID:
18158775
22.

The effects of a biocide and a surfactant on the detachment of Pseudomonas fluorescens from glass surfaces.

Simões M, Simões LC, Cleto S, Pereira MO, Vieira MJ.

Int J Food Microbiol. 2008 Feb 10;121(3):335-41. Epub 2007 Nov 21.

PMID:
18155793
23.

Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma.

Avilés A, Nambo MJ, Neri N, Castañeda C, Cleto S, Huerta-Guzmán J.

Med Oncol. 2007;24(2):227-30.

PMID:
17848748
24.

Door-to-dialysis time and daily hemodialysis in patients with leptospirosis: impact on mortality.

Andrade L, Cleto S, Seguro AC.

Clin J Am Soc Nephrol. 2007 Jul;2(4):739-44. Epub 2007 Jun 20.

25.

Dose dense (CEOP-14) vs dose dense and rituximab (CEOP-14 +R) in high-risk diffuse large cell lymphoma.

Avilés A, Nambo MJ, Neri N, Cleto S, Castañeda C, Huerta-Guzmàn J, Murillo E, Contreras M, Talavera A, González M.

Med Oncol. 2007;24(1):85-9.

PMID:
17673816
26.

Rituximab and dose dense chemotherapy in primary breast lymphoma.

Avilés A, Castañeda C, Neri N, Cleto S, Nambo MJ.

Haematologica. 2007 Aug;92(8):1147-8.

27.

Rituximab and escalated chemotherapy in elderly patients with aggressive diffuse large-cell lymphoma: a controlled clinical trial.

Avilés A, Nambo MJ, Castañeda C, Cleto S, Neri N, Murillo E, Huerta-Guzmán J, Contreras M.

Cancer Biother Radiopharm. 2007 Apr;22(2):194-9.

PMID:
17600466
28.

CMED in the treatment of nasal natural killer cell lymphoma with distant metastases.

Avilés A, Cleto S, Castañeda C, Nambo MJ.

Hematology. 2007 Jun;12(3):241-4.

PMID:
17558700
29.

Influence of biofilm composition on the resistance to detachment.

Simões M, Cleto S, Pereira MO, Vieira MJ.

Water Sci Technol. 2007;55(8-9):473-80.

PMID:
17547019
30.

Antimicrobial mechanisms of ortho-phthalaldehyde action.

Simões M, Simões LC, Cleto S, Machado I, Pereira MO, Vieira MJ.

J Basic Microbiol. 2007 Jun;47(3):230-42.

PMID:
17518416
31.

Addition of a short course of chemotherapy did not improve outcome in patients with localized marginal B-cell lymphoma of the orbit.

Avilés A, Neri N, Calva A, Huerta-Guzmán J, Cleto S, Nambo MJ.

Oncology. 2006;70(3):173-6. Epub 2006 Jun 7.

PMID:
16763405
32.

Surgery and chemotherapy versus chemotherapy as treatment of high-grade MALT gastric lymphoma.

Avilés A, Neri N, Nambo MJ, Huerta-Guzman J, Cleto S.

Med Oncol. 2006;23(2):295-300.

PMID:
16720930
33.

Residual disease after chemotherapy in aggressive malignant lymphoma: the role of radiotherapy.

Avilés A, Neri N, Delgado S, Pérez F, Nambo MJ, Cleto S, Talavera A, Huerta-Guzmán J.

Med Oncol. 2005;22(4):383-7.

PMID:
16260856
34.

Primary breast lymphoma: results of a controlled clinical trial.

Avilés A, Delgado S, Nambo MJ, Neri N, Murillo E, Cleto S.

Oncology. 2005;69(3):256-60. Epub 2005 Sep 15.

PMID:
16166814
35.

Novel therapy in multiple myeloma.

Avilés A, Neri N, Nambo MJ, Cleto S, Castañeda C, González M, Talavera A, Huerta-Guzmán J.

Invest New Drugs. 2005 Oct;23(5):411-5.

PMID:
16133792
36.

Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy.

Avilés A, Neri N, Nambo JM, Huerta-Guzman J, Talavera A, Cleto S.

Leuk Lymphoma. 2005 Jul;46(7):1023-8.

PMID:
16019553
37.

Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trial.

Avilés A, Nambo MJ, Neri N, Talavera A, Cleto S.

Med Oncol. 2005;22(1):57-62.

PMID:
15750197
38.

Biological modifiers as cytoreductive therapy before stem cell transplant in previously untreated patients with multiple myeloma.

Avilés A, Nambo MJ, Neri N, Murillo E, Castañeda C, Cleto S, Talavera A, González M.

Ann Oncol. 2005 Feb;16(2):219-21.

PMID:
15668273
39.

Intensive chemotherapy in the treatment of aggressive diffuse large B-cell lymphoma: malignant lymphoma.

Avilés A, Nambo MJ, Neri N, Talavera A, Castañeda C, Murillo E, Cleto S, Huerta-Guzmán J.

Med Oncol. 2004;21(3):269-72.

PMID:
15456955
40.

Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome.

Avilés A, Fernándezb R, Pérez F, Nambo MJ, Neri N, Talavera A, Castañeda C, González M, Cleto S.

Leuk Lymphoma. 2004 Jul;45(7):1385-9. Retraction in: Polliack A, Van Besien K, Seymour J, Treadway A. Leuk Lymphoma. 2013 Jul;54(7):1571.

PMID:
15359637
41.

Treatment of advanced Hodgkin's disease: EBVD versus intensive brief chemotherapy.

Avilés A, Cleto S, Neri N, Huerta-Guzmán J, Talavera A, Castañeda C, González M.

Leuk Lymphoma. 2003 Aug;44(8):1361-5.

PMID:
12952230
42.

Chemotherapy plus interferon-alpha2b versus chemotherapy in the treatment of follicular lymphoma.

Neri N, Avilés A, Cleto S, Díaz N, Talavera A, García EL, Díaz-Maqueo JC.

J Hematother Stem Cell Res. 2001 Oct;10(5):669-74.

PMID:
11672513
43.

Evaluation on a six-dose treatment of anti CD 20 monoclonal antibody in patients with refractory follicular lymphoma.

Avilés A, Talavera A, Díaz-Maqueo JC, García EL, Cleto S, Neri N.

Cancer Biother Radiopharm. 2001 Apr;16(2):159-62.

PMID:
11385962
44.

Rituximab in the treatment of refractory follicular lymphoma -- six doses are better than four.

Avilés A, León MI, Díaz-Maqueo JC, García EL, Cleto S, Neri N.

J Hematother Stem Cell Res. 2001 Apr;10(2):313-6.

PMID:
11359679
45.

Second lethal events associated with treatment for Hodgkin's disease: a review of 2980 patients treated in a single Mexican institute.

Avilés A, Neri N, Cuadra I, Alvarado I, Cleto S.

Leuk Lymphoma. 2000 Oct;39(3-4):311-9.

PMID:
11342311
46.
47.

Angiocentric nasal T/natural killer cell lymphoma: a single centre study of prognostic factors in 108 patients.

Avilés A, Díaz NR, Neri N, Cleto S, Talavera A.

Clin Lab Haematol. 2000 Aug;22(4):215-20.

PMID:
11012633
48.

Dexamethasone, all trans retinoic acid and interferon alpha 2a in patients with refractory multiple myeloma.

Avilés A, Rosas A, Huerta-Guzmán J, Talavera A, Cleto S.

Cancer Biother Radiopharm. 1999 Feb;14(1):23-6.

PMID:
10850283
49.

High Dose Chemotherapy in the Treatment of Poor Prognosis Malignant Lymphoma.

Avilés A, Talavera A, Díaz-Maqueo JC, Cleto S, Díaz NR, García EL.

Hematology. 1998;3(3):229-33. doi: 10.1080/10245332.1998.11746395.

PMID:
27416532

Supplemental Content

Support Center